Neuraxis, Inc. (NRXS) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Neuraxis, Inc. is a growth-stage medical device company specializing in neuromodulation therapies, primarily marketing the IB-STIM device for functional abdominal pain in children. The company is a non-accelerated filer and an emerging growth company. As of August 8, 2024, there were 6,841,621 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|
| Net Sales | $611,500 | $1,258,135 | $1,451,131 |
| Gross Profit | $538,042 | $1,109,596 | $1,287,418 |
| Gross Margin | 88.0% | 88.2% | 88.7% |
| Operating Loss | $(2,206,832) | $(4,038,952) | $(2,013,814) |
| Net Loss | $(2,917,710) | $(5,038,361) | $(4,409,022) |
| Loss Per Share (Basic/Diluted) | $(0.42) | $(0.73) | $(2.39) |
| Cash and Equivalents (End of Period) | $1,765,274 | ||
| Working Capital Deficit | $(5,482,316) | ||
| Convertible Notes Payable (Current) | $4,728,538 |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 13.3% year-over-year for the six months ended June 30, 2024. Management attributes this to a strategic focus on securing insurance coverage and fewer shipments to customers transitioning to insurance reimbursement protocols.
- Expense Surge: General and Administrative (G&A) expenses increased 65.5% year-over-year to $4.95 million. This was driven by costs associated with being a public company (legal, insurance, investor relations), severance charges for the former COO, stock-based compensation ($227,000), and one-time advisory costs.
- Debt Financing: The company issued approximately $4.94 million in convertible promissory notes during the first half of 2024 to fund operations, significantly increasing current liabilities.
- Non-Cash Charges: Significant non-cash expenses included amortization of debt discounts ($85,500) and settlements of pre-IPO shareholder claims recorded as other expenses ($577,081).
Outlook, Risks, and Contingencies
- Going Concern: The company has incurred losses since inception and maintains a stockholders' deficit of $5.26 million. Management states that existing cash is sufficient only through the end of 2024. Substantial doubt exists regarding the company's ability to continue as a going concern without additional financing or increased revenue.
- Liquidity Strategy: Future capital requirements depend on securing insurance coverage for the IB-STIM device and raising additional funds through public or private offerings of debt or equity.
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting due to limited staff and a lack of segregation of duties. A restatement of prior interim financial statements was required.
- Litigation: The company is defending against lawsuits alleging misrepresentation regarding Medicare reimbursement for its NeuroStim device. While a summary judgment was granted in one case, appeals and related claims remain pending.
- Settlements: The company settled claims with pre-IPO Series A Preferred Stock shareholders by issuing common stock, resulting in significant one-time expenses.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.77 million cash balance to cover operations through the end of 2024 given the high burn rate.
- Debt Conversion Terms: Review the terms of the $4.73 million in convertible notes, specifically the conversion price ($2.38) and the potential for significant dilution if shareholder approval for Series B Preferred Stock is not obtained by August 15, 2024.
- Insurance Adoption: Assess progress in securing commercial insurance coverage, which management cites as the primary driver for future revenue growth.
- Internal Control Remediation: Monitor the company's progress in hiring staff and implementing controls to address the identified material weaknesses.
- Litigation Status: Track the outcome of pending appeals regarding the RICO Act and misrepresentation claims, which could result in significant liabilities.